Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9485466 | 0.92 | CYP2C19 (0.48) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL2359048 | 0.82 | TSHR (0.36) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL9483954 | 0.78 | ALDH1A1 (0.46) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL17947361 | 0.72 | ALDH1A1 (0.34) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL6602222 | 0.71 | CYP2D6 (0.39) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL284431 | 0.70 | CYP2C19 (0.42) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL20347175 | 0.70 | CYP2C19 (0.48) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL15837219 | 0.69 | ALDH1A1 (0.32) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL347366 | 0.69 | CYP2C19 (0.46) | CYP2C19HIF1ACYP2D6TSHRHMGCR | |
| SCHEMBL1547881 | 0.69 | CYP2C19 (0.46) | CYP2C19HIF1ACYP2D6TSHRHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | ACTELION PHARMACEUTICALS, LTD. (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8501818-B2 | Stabilized compositions of alkylating agents and methods of using same | CEPTARIS THERAPEUTICS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20100152300-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | HELSINN HEALTHCARE SA (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | CYP2C19 4364/4885HIF1A 2349/4885CYP2D6 4744/4885 |
| US-20100152300-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | MGMT, UNG, ERCC5 | CYP2C19 4221/4885HIF1A 3058/4885CYP2D6 3853/4885 |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | MGMT, UNG, OGG1 | CYP2C19 3134/4885HIF1A 1158/4885CYP2D6 2643/4885 |
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | MGMT, UNG, ERCC5 | CYP2C19 4221/4885HIF1A 3058/4885CYP2D6 3853/4885 |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | CYP2C19 4364/4885HIF1A 2349/4885CYP2D6 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.